Ascletis announced that the clinical trial application for ASC11, an oral 3CLpro inhibitor, has been accepted by the NMPA

Ascletis WeChat public account today said that its application for a clinical trial (IND) of ASC11, an oral candidate for COVID-19 ("COVID-19") oral candidate protease (3CLpro), has been accepted by the National Medical Products Administration of China ("NMPA").

In antiviral cell experiments infected with the new coronavirus, ASC11 showed much higher anti-novel coronavirus activity than other 3CLpro inhibitors such as nirmatevir, S-217622, PBI-0451 and EDP-235. ASC11 maintains potent antiviral activity against a variety of widely circulating Omicron variants such as BA.1 and BA.5. In animal models of novel coronavirus infection, ASC11 also exhibits potent antiviral activity.

ASC11 is an oral small molecule candidate independently developed using a variety of proprietary technologies, including molecular simulation docking. Ascletis has filed numerous patent applications worldwide for ASC11 and related compounds and their use in the treatment of viral diseases.

About Karitting

Ascletis is a company listed on the Hong Kong Stock Exchange (1672. HK) is an innovative R&D-driven biotechnology company covering the entire value chain from new drug development to manufacturing and commercialization. Led by Ascletis' management team with deep expertise and proven track record, Ascletis focuses on three areas of healthcare with unmet clinical needs: viral diseases, non-alcoholic fatty liver disease and oncology, and takes a global perspective. With superior execution, Ascletis rapidly advances the development of its drug pipeline and strives to take the lead in the international competition. Ascletis currently has three commercialized products, ritonavir, gonovic ® and synnexal, ® as well as 22 drug candidates. Cutting-edge drug candidates include ASC22 (functional cure for hepatitis B), ASC10 and ASC11 (oral small molecule anti-coronavirus drugs), ASC40 (recurrent glioblastoma), ASC42 (primary biliary cholangitis) and ASC40 (acne).